SCHEMBL30154501

SCHEMBL30154501

N#Cc1cc(F)c(CC(=O)O)cc1F

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.44
AKR1B1 P15121 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.37
FFAR1 O14842 3/20 0.36
FFAR4 Q5NUL3 3/20 0.36
CXCL8 P10145 2/20 0.36
DPP4 P27487 1/20 0.35
CNR2 P34972 1/20 0.35
TSHR P16473 1/20 0.34
TSPO P30536 1/20 0.34
DRD3 P35462 1/20 0.34
S1PR1 P21453 1/20 0.34
PKM P14618 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2723062 1.00 TRPV4 (0.44) TRPV4AKR1B1RXRARXRBRXRG
SCHEMBL297085 0.85 MRGPRX4 (0.41) TRPV4AKR1B1RXRARXRBRXRG
SCHEMBL2730017 0.81 HSD17B10 (0.48) AKR1B1CXCL8TSHRTDP1
SCHEMBL286608 0.81 STING1 (0.44) PTGDR2TSHRTDP1
SCHEMBL23832263 0.80 MAPT (0.40) TRPV4AKR1B1TSHR
SCHEMBL30154484 0.80 MAPT (0.40) TRPV4AKR1B1TSHR
SCHEMBL332576 0.78 CXCL8 (0.43) AKR1B1CXCL8DPP4TSHRPKM
SCHEMBL29362137 0.78 CXCL8 (0.43) AKR1B1CXCL8DPP4TSHRPKM
SCHEMBL365265 0.77 TRPV4 (0.50) TRPV4AKR1B1
SCHEMBL13766377 0.77 TRPV4 (0.50) TRPV4AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823097-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2025-04-15 CN disclosed
CN-115551845-B PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2025-02-28 CN disclosed
CN-115551845-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-30 CN disclosed